| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 239 | 2017 |
| Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a … RS Herbst, HT Arkenau, R Santana-Davila, E Calvo, L Paz-Ares, ... The Lancet Oncology 20 (8), 1109-1123, 2019 | 235 | 2019 |
| Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open‐label, phase I trial (JVDF) HT Arkenau, J Martin‐Liberal, E Calvo, N Penel, MG Krebs, RS Herbst, ... The oncologist 23 (12), 1407-e136, 2018 | 141 | 2018 |
| RIG-I–like receptor LGP2 protects tumor cells from ionizing radiation RC Widau, AD Parekh, MC Ranck, DW Golden, KA Kumar, RF Sood, ... Proceedings of the National Academy of Sciences 111 (4), E484-E491, 2014 | 87 | 2014 |
| STING promotes homeostasis via regulation of cell proliferation and chromosomal stability DRE Ranoa, RC Widau, S Mallon, AD Parekh, CM Nicolae, X Huang, ... Cancer research 79 (7), 1465-1479, 2019 | 75 | 2019 |
| Protein phosphatase 2A (PP2A) holoenzymes regulate death-associated protein kinase (DAPK) in ceramide-induced anoikis RC Widau, Y Jin, SA Dixon, BE Wadzinski, PJ Gallagher Journal of biological chemistry 285 (18), 13827-13838, 2010 | 74 | 2010 |
| Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab AX Zhu, RS Finn, YK Kang, CJ Yen, PR Galle, JM Llovet, E Assenat, ... British journal of cancer 124 (8), 1388-1397, 2021 | 51 | 2021 |
| Effect of ramucirumab on ALBI grade in patients with advanced HCC: results from REACH and REACH-2 M Kudo, PR Galle, G Brandi, YK Kang, CJ Yen, RS Finn, JM Llovet, ... JHEP Reports 3 (2), 100215, 2021 | 41 | 2021 |
| Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2 M Kudo, PR Galle, JM Llovet, RS Finn, A Vogel, K Motomura, E Assenat, ... Liver International 40 (8), 2008-2020, 2020 | 33 | 2020 |
| p19Arf Represses Platelet-Derived Growth Factor Receptor β by Transcriptional and Posttranscriptional Mechanisms RC Widau, Y Zheng, CY Sung, A Zelivianskaia, LE Roach, ... Molecular and cellular biology 32 (21), 4270-4282, 2012 | 21 | 2012 |
| Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell Lung Cancer (RELAY): Phase Ib … M Reck, EB Garon, L Paz-Ares, S Ponce, JC Jaime, O Juan, E Nadal, ... Clinical lung cancer 19 (3), 213-220. e4, 2018 | 19 | 2018 |
| Delta-like 1-Lysine613 regulates notch signaling L Zhang, RC Widau, BP Herring, PJ Gallagher Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1813 (12), 2036-2043, 2011 | 17 | 2011 |
| Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following non–sorafenib systemic therapy: An expansion cohort of REACH-2 RS Finn, T Yau, CH Hsu, EN De Toni, L Goyal, PR Galle, SK Qin, S Rao, ... The Oncologist 27 (12), e938-e948, 2022 | 16 | 2022 |
| Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab M Reig, PR Galle, M Kudo, R Finn, JM Llovet, AL Metti, WR Schelman, ... Liver International 41 (3), 598-607, 2021 | 16 | 2021 |
| Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors AX Zhu, Y Lin, D Ferry, RC Widau, A Saha Immunotherapy 14 (16), 1341-1351, 2022 | 13 | 2022 |
| Prognostic and predictive factors in patients with advanced HCC and elevated alpha-fetoprotein treated with ramucirumab in two randomized phase III trials JM Llovet, AG Singal, A Villanueva, RS Finn, M Kudo, PR Galle, M Ikeda, ... Clinical Cancer Research 28 (11), 2297-2305, 2022 | 11 | 2022 |
| RANGE study investigators: Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... Lancet 390 (10109), 2266-2277, 2017 | 10 | 2017 |
| Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers MT Spiotto, M Pytynia, GFF Liu, MC Ranck, R Widau Journal of oral & maxillofacial research 4 (1), 2013 | 10 | 2013 |
| Ramucirumab for patients with hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib treatment: exploratory analysis of REACH-2 trial results by albumin … G Brandi, M Kudo, YK Kang, CJ Yen, R Finn, P Galle, JM Llovet, ... EASL HCC Summit, 14-16, 2019 | 9 | 2019 |
| Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy. RS Herbst, I Chau, DP Petrylak, HT Arkenau, JC Bendell, ... Journal of Clinical Oncology 36 (15_suppl), 3059-3059, 2018 | 7 | 2018 |
